KEYNOTE-042: is lowering the PD-L1 threshold for first-line pembrolizumab monotherapy a good idea?

Lignende værker

• Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
  af: Isaacs, James, et al.
  Udgivet: (2020)
• KEYNOTE-042 and the role for single agent pembrolizumab in patients with PD-L1 tumor proportion score 1–49%
  af: Morgensztern, Daniel
  Udgivet: (2019)
• KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit
  af: Cummings, Amy Lauren, et al.
  Udgivet: (2019)
• Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?
  af: Theelen, Willemijn S. M. E., et al.
  Udgivet: (2019)
• Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain
  af: Pacheco, Jose M., et al.
  Udgivet: (2019)